Clinical Trial Update: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Everolimus and Imatinib Mesylate for metastatic or unresectable kidney cancer; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-10-05